SCHEMBL23958638

SCHEMBL23958638

CCOC(=O)c1c(F)cnc(-c2ccc(F)cc2)c1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.50
KDM4E B2RXH2 5/20 0.50
HPGD P15428 4/20 0.50
GAA P10253 3/20 0.50
MAPT P10636 3/20 0.50
MAPK1 P28482 2/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
PKM P14618 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
TP53 P04637 1/20 0.48
GRM6 O15303 1/20 0.48
PRKCZ Q05513 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.47
TRPM8 Q7Z2W7 1/20 0.45
ADORA3 P0DMS8 2/20 0.45
GABRA2 P47869 1/20 0.44
GABRB2 P47870 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30211242 1.00 ALDH1A1 (0.50) ALDH1A1KDM4EHPGDGAAMAPT
SCHEMBL23930239 0.78 ALDH1A1 (0.50) ALDH1A1KDM4EHPGDGAAMAPT
SCHEMBL30007091 0.78 ALDH1A1 (0.50) ALDH1A1KDM4EHPGDGAAMAPT
SCHEMBL31297236 0.76 HTT (0.41) ALDH1A1KDM4EHPGDGAAMAPT
SCHEMBL20638918 0.76 HTT (0.41) ALDH1A1KDM4EHPGDGAAMAPT
SCHEMBL23930240 0.76 JMJD6 (0.41) ALDH1A1KDM4EHPGDGAAMAPT
SCHEMBL30007197 0.76 JMJD6 (0.41) ALDH1A1KDM4EHPGDGAAMAPT
SCHEMBL3407583 0.74 ALDH1A1 (0.64) ALDH1A1KDM4EHPGDGAAMAPT
SCHEMBL286034 0.74 ALDH1A1 (0.61) ALDH1A1KDM4EHPGDGAAMAPT
SCHEMBL7566003 0.74 ALDH1A1 (0.57) ALDH1A1KDM4EHPGDGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203004-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 US disclosed
US-20230203004-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 US disclosed
CN-115461336-A RSV inhibiting 3-substituted quinoline and cinnoline derivatives 爱尔兰詹森科学公司 2022-12-09 CN disclosed
WO-2021214136-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203004-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES ACE2, SIRT7, ACE ALDH1A1 1630/4885KDM4E 3733/4885HPGD 2976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.